Geron Corp

GERN Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of GERN by members of U.S. Congress

Politician Type Traded
Ro Khanna House / D Purchase $15,001 - $50,000 N/A
GERN Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
GERN Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
GERN Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in GERN holdings by institutional investors

Insider Trading

Quarterly net insider trading by GERN's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $60,000 Oct 23, 2025 Issue: Energy/Nuclear
  • $30,000 Oct 20, 2025 Issue: Medicare/Medicaid
  • $60,000 Jul 21, 2025 Issue: Energy/Nuclear
  • $30,000 Jul 20, 2025 Issue: Medicare/Medicaid
  • $30,000 Apr 19, 2025 Issue: Medicare/Medicaid
  • $30,000 Jan 20, 2025 Issue: Health Issues
  • $20,000 Oct 21, 2024 Issue: Health Issues
  • $30,000 Jul 21, 2024 Issue: Health Issues
  • $30,000 Apr 22, 2024 Issue: Health Issues
  • $30,000 Jan 22, 2024 Issue: Health Issues
  • $10,000 Oct 19, 2023 Issue: Health Issues
Corporate Lobbying

GERN Estimated quarterly lobbying spending

Revenue Breakdown

GERN Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
GERN Income Statement
GERN Balance Sheet
GERN Cash Flow
U.S. Patents

New GERN patent grants

  • Patent Title: Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors Apr. 24, 2018
  • Patent Title: Rna amidates and thioamidates for rnai Nov. 21, 2017
  • Patent Title: Oligonucleotide compositions and methods of making the same Oct. 24, 2017
  • Patent Title: C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders Sep. 26, 2017
  • Patent Title: 2′-arabino-fluorooligonucleotide n3′→p5′ phosphoramidates: their synthesis and use Sep. 19, 2017
  • Patent Title: Compounds having anti-adhesive effects on cancer cells Aug. 15, 2017
  • Patent Title: Phosphorodiamidate backbone linkage for oligonucleotides Jul. 18, 2017
  • Patent Title: Modified oligonucleotides for telomerase inhibition May. 23, 2017
  • Patent Title: Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr Apr. 18, 2017
  • Patent Title: Method for identification of sensitivity of a patient to telomerase inhibition therapy Apr. 11, 2017
  • Patent Title: Guanine analogs as telomerase substrates and telomere length affectors Mar. 14, 2017
  • Patent Title: Oligonucleotide conjugates Feb. 21, 2017
  • Patent Title: Modified oligonucleotides for telomerase inhibition Aug. 02, 2016
  • Patent Title: Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms Jun. 28, 2016
  • Patent Title: Synthesis of protected 3′-amino nucleoside monomers Jun. 14, 2016
  • Patent Title: C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders Jan. 05, 2016
  • Patent Title: Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors Dec. 01, 2015
  • Patent Title: Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors Oct. 13, 2015
  • Patent Title: Rna amidates and thioamidates for rnai Sep. 15, 2015
  • Patent Title: Oligonucleotide conjugates Jul. 07, 2015
  • Patent Title: 2′-arabino-fluorooligonucleotide n3′→p5′ phosphoramidates: their synthesis and use Dec. 09, 2014
  • Patent Title: Method for identification of sensitivity of a patient to telomerase inhibition therapy Nov. 04, 2014
  • Patent Title: Nucleic acids encoding inactive variants of human telomerase Aug. 05, 2014
  • Patent Title: Compounds having anti-adhesive effects on cancer cells Jul. 22, 2014
  • Patent Title: Synthesis of protected 3′-amino nucleoside monomers Jun. 10, 2014
  • Patent Title: Method for eliciting an immune response to human telomerase reverse transcriptase Apr. 29, 2014
  • Patent Title: Synthetic surfaces for culturing stem cell derived cardiomyocytes Oct. 22, 2013
  • Patent Title: Protocols for making hepatocytes from embryonic stem cells Oct. 01, 2013
  • Patent Title: Compound screening using chondrocytes derived from primate pluripotent stem cells Oct. 01, 2013
  • Patent Title: Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells Aug. 20, 2013
  • Patent Title: Oligonucleotide conjugates May. 14, 2013
  • Patent Title: In vitro differentiated cell and human embryonic stem cell population Apr. 23, 2013
  • Patent Title: Differentiation and enrichment of islet-like cells from human pluripotent stem cells Apr. 09, 2013
  • Patent Title: 2′-arabino-fluorooligonucleotide n3′→p5′ phosphoramidates: their synthesis and use Feb. 19, 2013
  • Patent Title: Synthetic surfaces for culturing cells in chemically defined media Jan. 15, 2013
  • Patent Title: Swellable (meth)acrylate surfaces for culturing cells in chemically defined media Dec. 11, 2012
  • Patent Title: Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes Dec. 04, 2012
  • Patent Title: Neural cell populations from primate pluripotent stem cells Aug. 28, 2012
  • Patent Title: Neural progenitor cell populations Aug. 28, 2012
  • Patent Title: Synthetic surfaces for culturing stem cell derived cardiomyocytes Aug. 14, 2012
  • Patent Title: Human telomerase catalytic subunit Aug. 07, 2012
  • Patent Title: Kit for detection of telomerase reverse transcriptase nucleic acids Jul. 17, 2012
  • Patent Title: Cns-tumor treatment method and composition Apr. 10, 2012
  • Patent Title: Use of tgf beta superfamily antagonists and neurotrophins to make neurons from embryonic stem cells Apr. 10, 2012
  • Patent Title: Differentiation of primate pluripotent cells to hepatocyte-lineage cells Apr. 03, 2012
  • Patent Title: Neural progenitor cell populations Apr. 03, 2012
  • Patent Title: Micro-carrier culture system for rapid expansion of human embryonic stem cells Jan. 17, 2012
  • Patent Title: Differentiation of primate pluripotent stem cells to hematopoietic lineage cells Jan. 10, 2012
  • Patent Title: Cancer treatment by combined inhibition of proteasome and telomerase activities Aug. 16, 2011
  • Patent Title: 2′-arabino-fluorooligonucleotide n3′-p5′ phosphoramidates: their synthesis and use Aug. 02, 2011
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to GERN from public contracts

GERN News

Recent insights relating to GERN

CNBC Recommendations

Recent picks made for GERN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in GERN

GERN Analyst Ratings

GERN Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
GERN Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $GERN stock a Buy, Sell, or Hold?

  • What is the price target for $GERN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

GERN Top Shareholders
Shareholder
Shares Held
GERN Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $GERN stock?

  • Who owns the most shares of $GERN stock?

  • What funds own $GERN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

GERN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view GERN Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About GERN

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

  • Address Foster City, CA
  • Market Cap 715.0 million
  • Employees 229
  • Industrial Classification Pharmaceutical Preparations
Back To Top